Phenotypic assays with iPSC-derived cells help deciphering the full range of molecular mechanisms affected by the pathology. Efficacy and toxicity assays become relevant.
Straightforward answers with
iPSC and phenotypic assays
250 lead compounds screened from a million compounds enter pre-clinical testing
10 of them will proceed to clinical trial
1 will be approved by regulatory authorities
For one-third, pre-clinical investigations of the drug development process are performed using cellular tools.
Increasing the relevance of those tools to the pathophysiological situation greatly improves drug screening efficacy and limits the occurrence of false-positive molecules
Our assays are designed to monitor crucial physiological functions, including:
axonal elongation and branching (Neural stem cells)
Shift from target-based to phenotypic assays with PhenoTests
Why iPSC ?
Induced pluripotent stem cells (iPSC) are cells with the characteristics of embryonic stem cells, generated from an adult cell.
iPSC possess the ability to self-renew, or multiply identically in vitro. They also retain the ability to form any type of cell of the Human body, a property called pluripotency.
Self-renewal, or unlimited expansion, allows generating billions of cells nearly identical to perform long-term studies. Pluripotency affords the possibility to obtain all cellular models needed to study a single pathophysiological situation.
IPSC are unique tools for pathophysiological modeling and compound assessment. They are used worldwide by more than 2000 research teams, in academia and the pharmaceutical and cosmetic industry.
Phenocell has acquired a premium expertise in human iPSC production (more than 180 iPSC lines since inception) and had developed robust processes to differentiate iPSC into skin cells.
Our offer of skin cells (sebocytes, melanocytes and keratinocytes) from a variety of ethnic backgrounds is unique worldwide.
Each cell type comes with a panel of bioassays to target the main functions and dysfunction of the human skin.